AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Results of Operations and Financial ConditionItem 2.02Results of Operations and Financial Condition.
On May 2, 2018, Avadel Pharmaceuticals plc (the “Company”) issued a press release announcing its earnings for the quarter ended March 31, 2018. That press release is attached as Exhibit 99.1 and is incorporated herein by reference.
The information responsive to this Item 2.02 of this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 (the “Securities Act”) or the Exchange Act, except as may be expressly set forth by specific reference in such a filing.
Item 7.01 Regulation FD Disclosure.
On May 2, 2018, the Company posted to its website a set of presentation materials that it will use during its earnings call and webcast to assist participants with understanding the Company’s financial results for the quarter ended March 31, 2018 . A copy of this presentation is attached hereto as Exhibit 99.2.
The information responsive to this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as may be expressly set forth by specific reference in such filing.
Item 8.01 Other Events
On May 1, 2018, the Company issued a press release announcing that it launched NOCTIVA™, the first and only FDA-approved product for the treatment of nocturia due to nocturnal polyuria in adults. That press release is attached as Exhibit 99.3 and is incorporated herein by reference.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
|
99.1 |
Press release dated May 2, 2018, issued by Avadel Pharmaceuticals plc * |
|
99.2 |
Presentation materials dated May 2, 2018, issued by Avadel Pharmaceuticals plc* |
|
99.3 |
Press release dated May 1, 2018, issued by Avadel Pharmaceuticals plc* |
* This information shall be deemed to be "furnished" and not filed herewith.
AVADEL PHARMACEUTICALS PLC ExhibitEX-99.1 2 q12018earningsrelease.htm EXHIBIT 99.1 Exhibit Avadel Pharmaceuticals Reports First Quarter 2018 ResultsNOCTIVA™ launch underway across the U.S.FT 218 granted Orphan Drug DesignationGenerated revenue of $33.3 million Dublin,…To view the full exhibit click here
